OvaScience Inc (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new fertility treatment options, announced its plans for 2016. OvaScience will present in a live webcast at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 14, 2016, at 9:30 a.m. PST (12:30 p.m. EST) from the Westin St. Francis Hotel in San Francisco.

OvaScience’s goals for 2016 include building its global infrastructure to support the availability of the Company’s AUGMENTSM treatment and driving the development of OvaPrimeSM and OvaTureSM treatments, with a focus on expanding in key strategic regions such as Japan, Western Europe and Canada.

“OvaScience is committed to offering new fertility treatments for patients,” said Michelle Dipp, M.D., Ph.D., Executive Chairman and Chief Executive Officer of OvaScience. “In 2016, we plan to expand access to the AUGMENT treatment, determine the OvaPrime treatment’s clinical feasibility by the end of the year and continue our development of the first zero-hormone fertility treatment, OvaTure.”

  • AUGMENT Treatment

Building on the positive patient experiences to date, OvaScience plans to expand the network of clinics and clinicians offering the AUGMENT treatment in 2016, focusing in Japan, Western Europe and Canada. The Company also announced it will be working with clinic partners to obtain prospective patient experience data, including theIVI Group, the largest IVF clinic network in the world. In 2016, the IVI Group plans to continue enrollment of patients in its controlled, double-blind, prospective and randomized egg allocation study of the AUGMENT treatment. This adaptive study compares standard IVF to AUGMENT.

In connection with AUGMENT’s recent approval in Japan, OvaScience plans to build the infrastructure to support a non-commercial preceptorship training program in Japan, one of the largest IVF markets in the world.

The AUGMENT treatment is designed to improve egg health by supplementing a woman’s mature eggs with mitochondria from egg precursor (EggPCSM) cells, immature egg cells found inside the protective ovarian lining, during IVF. The treatment is not available in the U.S.

  • OvaPrime Treatment

In December 2015, OvaScience commenced a non-commercial preceptorship training program with the OvaPrime treatment outside the U.S. OvaScience will decide whether to progress the program, based on data, by the end of 2016.

The OvaPrime treatment is a potential fertility treatment that could enable a woman who makes too few or no eggs to increase her egg reserve. Poor egg reserve affects approximately 25 percent of those seeking fertility treatment. The OvaPrime treatment is designed to transfer a woman’s EggPC cells to her own ovary where they may mature into fertilizable eggs during a standard IVF process. The treatment is not available in the U.S.

  • OvaTure Treatment

In 2016, OvaScience will continue development of the OvaTure procedure, with a goal of further understanding the clinical path forward. The aim is to characterize EggPC-derived mature eggs.

The OvaTure treatment is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections by maturing EggPC cells into eggs outside the body. It may be an option for women with compromised eggs, who are unable to make eggs, or who may be unwilling or unable to undergo hormone hyperstimulation, such as women diagnosed with cancer. (Original Source)

Shares of OvaScience Inc closed last Friday at $8, down $0.22 or -2.68%. OVAS has a 1-year high of $55.69 and a 1-year low of $7.81. The stock’s 50-day moving average is $9.87 and its 200-day moving average is $17.20.

On the ratings front, OvaScience has been the subject of a number of recent research reports. In a report issued on December 14, Oppenheimer analyst Rohit Vanjani assigned a Buy rating on OVAS, with a price target of $16, which represents a potential upside of 100.0% from where the stock is currently trading. Separately, on November 9, Leerink Swann’s Paul Matteis downgraded the stock to Hold and has a price target of $14.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Rohit Vanjani and Paul Matteis have a total average return of 14.2% and -30.8% respectively. Vanjani has a success rate of 52.8% and is ranked #119 out of 3610 analysts, while Matteis has a success rate of 7.4% and is ranked #3555.

OvaScience Inc is a life science company engaged in discovery, development, and commercialization of new fertility treatments. Its patented technology is based on egg precursor cells found in the outer layer of a woman’s own ovaries.